BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.18.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Global Biodefense
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231113
DTEND;VALUE=DATE:20231115
DTSTAMP:20231017T165957Z
CREATED:20231016T173338Z
LAST-MODIFIED:20231017T165957Z
UID:59385-1699833600-1700006399@globalbiodefense.com
SUMMARY:BARDA Industry Day - BID2023
DESCRIPTION:The annual BARDA Industry Day (BID) conference will be held 13-14 November 2023 in Washington DC and via virtual participation. \nBID2023: Driving Innovation for Preparedness & Response will feature presentations from BARDA leadership\, U.S. government partners\, and industry on medical countermeasure (MCM) priorities and public health innovation. Attendees will also have an informal opportunity to interact with BARDA and ASPR teams and identify areas of potential collaboration in the field of MCM research and development. \nThe event lineup will have an assortment of BARDA program briefings\, guest speakers\, networking opportunities\, and specialized breakout sessions. Content will focus on BARDA’s efforts to collaborate across government and industry to continually innovate MCMs to address current and future health security threats. \nBARDA’s Influenza and Emerging Infectious Diseases Division (IEIDD) will give a broad ranging presentation on BARDA’s strategy for vaccine development through licensure including harmonized clinical trials\, centralized immune endpoint assays\, determination of correlates of protection\, lessons learned from the COVID-19 vaccine portfolio\, and assay-generated data for accelerated decision making. \nBARDA’s Division of Chemical\, Biological\, Radiological\, And Nuclear (CBRN) Countermeasures will provide an overview of its strategic priorities for branch and division level efforts. Among these priorities include CBRN’s plans to expand the nation’s capabilities to respond to any CBRN health security incident\, whether naturally occurring or intentional. Following the presentations\, a moderated Q&A panel will provide a deeper dive into how division-level priorities can shape medical countermeasure development going forward. \nBARDA program representatives\, industry partners\, and developers will provide an overview of animal models developed in laboratories of network performers funded through the Biological\, Chemical\, and Radiological Indefinite Delivery/Indefinite Quantity (ID/IQ) contract. In addition\, selected product developers funded by BARDA’s nonclinical network will share information on the use of animal models in efforts to license products for use against biodefense threats. \nBARDA’s Biopharmaceutical Manufacturing Preparedness (BioMaP) program has a three-pronged approach to address key vaccine manufacturing gaps to bring the nation up to the speed and scale required for future public health emergencies. In this session\, the BioMaP team will discuss these three components: the BioMaP-Consortium\, the Exercise (BioMaP-X)\, and the BioMaP Workforce Development (BioMaP-W). Join BARDA’s Pharmaceutical Countermeasures Infrastructure Division (PCI) to learn about these different aspects of the BioMaP program. \nSpeakers from the U.S. Food and Drug Administration’s (FDA) Medical Countermeasures Initiative will also address the coordination of emergency activities involving products regulated by the FDA’s Center for Drug Evaluation and Research (CDER)\, Center for Biologics Evaluation and Research (CBER)\, and Center for Devices and Radiological Health (CDRH). \nThe Division of Chemical\, Biological\, Radiological and Nuclear (CBRN)\, Division of Research\, Innovation and Ventures (DRIVe)\, and Division of Nonclinical Development (DNCD) will discuss microphysiological systems (MPS)/organ chips and how it aligns with BARDA’s portfolio. \nLearn more about BARDA Ventures – Global Health Investment Corporation (GHIC) partnership and join a discussion with GHIC on investment focus\, priorities\, and the landscape of venture investment in global health security. In addition\, learn more about the case study with Cytovale and Endpoint Health demonstrating how BARDA Ventures complements BARDA’s other investment vehicles to support MCM development and commercialization. \nA session on host-based diagnostics in sepsis will illuminate the strategic value of Host-Based Diagnostics (HBDs) in the infectious disease space and how to build a community around demonstrating the clinical utility of HBDs and streamlining their adoption and integration into practice. \nUncover BARDA’s latest initiative in clinical trial innovation pertaining to decentralized trials – the Decentralized Clinical Operations for Healthcare and Research (D-COHRe) strategic partnership. Topics include information on D-COHRe and BARDA’s fundamental interagency work towards advancing pandemic preparedness. \nPlease visit Medicalcountermeasures.gov to register. \n 
URL:https://globalbiodefense.com/event/barda-industry-day-bid2023/
LOCATION:Grand Hyatt Washington\, 1000 H St NW\, Washington DC\, 20001\, United States
CATEGORIES:Government Hosted,Industry Day
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2023/10/barda-industry-day-2023.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240222T090000
DTEND;TZID=America/New_York:20240222T160000
DTSTAMP:20240202T211124Z
CREATED:20240202T210750Z
LAST-MODIFIED:20240202T211124Z
UID:59861-1708592400-1708617600@globalbiodefense.com
SUMMARY:PACCARB Public Meeting
DESCRIPTION:The 24th Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) public meeting will be held virtually on February 22\, 2024. \nThis will be the second of two meetings to address the task provided to the PACCARB by the Secretary of HHS to address antimicrobial resistance globally. The focus of the meeting will be on international implementers and the gaps\, challenges\, and opportunities they see to combat AMR globally – specifically focusing on low- and middle-income countries. \nMeetings of the PACCARB are open to the public\, and virtual meetings can be accessed through the webcast. Registration to attend is not required but is encouraged. Attendees may also directly address the council on topics of antimicrobial resistance during public meetings. To provide written comments\, please e-mail your comments to CARB@hhs.gov. Written comments must be sent in by midnight February 15\, 2024 and should be limited to no more than one page. All public comments received prior to the deadline will be provided to the PACCARB council members. \nMeeting times are tentative and subject to change. Please visit HHS’ PACCARB website for the most current information.
URL:https://globalbiodefense.com/event/paccarb-public-meeting/
CATEGORIES:Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240223
DTEND;VALUE=DATE:20240224
DTSTAMP:20240218T175243Z
CREATED:20240218T174811Z
LAST-MODIFIED:20240218T175243Z
UID:60021-1708646400-1708732799@globalbiodefense.com
SUMMARY:Rapid Access to Products in Development (RAPID) Virtual Industry Day
DESCRIPTION:A Joint Industry Day for the Rapid Access to Products in Development (RAPID) program to be held virtually on 23 Feb 2024. \nThe Joint Program Executive Office for Chemical\, Biological\, Radiological\, and Nuclear Defense\, Enabling Biotechnologies (JPEO-CBRND-EB)\, develops\, manufactures and delivers safe and effective Medical Countermeasures (MCMs) for preparedness\, prevention\, protection\, response\, and recovery from CBRN threats. \nThe Rapid Access to Products in Development (RAPID) program is an integrated defense system composed of both physical MCM storage and fielding capabilities and a readily accessible information warehouse and sharing system (the RAPID Database). \nThe purpose of this Industry Day is to identify industry partners and capabilities to develop a RAPID Database capable of storing and organizing complex data and information related to CBRN MCMs such that it is intuitively accessible by a variety of end users during urgent planning and response situations. \nThe Database is intended to provide actionable information to assist CCMD-level decision makers when evaluating a RAPID MCM for potential administration to US warfighters; and JPEO- and CBDP-level decision makers when determining portfolio investment strategies or rapid response adjustments based on changing circumstances. \nThis Industry Day will include presentation by JPL EB as well as opportunities for industry partners to present their capabilities in one-on-one breakout sessions with representatives from the Government agencies. Industry partners will update Government stakeholders\, partners\, and end users on current efforts and capabilities. \nCompanies that wish to attend must register no later than 19 Feb 2024. More information is available at SAM.gov Notice ID W911SR-24-S-RAPID.
URL:https://globalbiodefense.com/event/medical-countermeasures-rapid-access-to-products-in-development-rapid-virtual-industry-day/
CATEGORIES:Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240228
DTEND;VALUE=DATE:20240301
DTSTAMP:20240226T215053Z
CREATED:20240226T215042Z
LAST-MODIFIED:20240226T215053Z
UID:60125-1709078400-1709251199@globalbiodefense.com
SUMMARY:Meeting of the Advisory Committee on Immunization Practices (ACIP)
DESCRIPTION:The CDC’s Advisory Committee on Immunization Practices (ACIP) will convene 28-29 February 2024 in Atlanta\, GA and via webcast. \nThe ACIP develops recommendations for U.S. immunizations\, including ages when vaccines should be given\, number of doses\, time between doses\, and precautions and contraindications. \nThe agenda will include the following: \n\nUpdate on chikungunya vaccine licensure and review of proposed policy options for chikungunya vaccine use among U.S. adults traveling abroad\, laboratory workers\, and pregnant and breastfeeding persons\nGuidance to use Td vaccine for those instances when receipt of the pertussis component is contraindicated\nCOVID-19 vaccination coverage\, effectiveness and economic analysis of additional dose recommendations\nNext steps for the COVID-19 vaccine program\nInterim estimates of 2023-24 seasonal influenza vaccine effectiveness\nSafety of LAIV4 in children with asthma\nInfluenza B/Yamagata update\nPolio Work Group deliberations on potential use of nOPV2 as an outbreak control measure in the US\nClinical considerations for children who received fractional dose inactivated polio vaccine (fIPV) in other countries\nPost-marketing safety surveillance of older adult RSV vaccination\nPreliminary Analysis of Guillain-Barré Syndrome (GBS) following RSV vaccination among adults 65 years and older\nOverview of Moderna’s investigational RSV Vaccine (mRNA-1345) in adults ≥60 years of age\nRevising the adolescent Meningococcal vaccine schedule\nCurrent epidemiology of invasive pneumococcal disease and pneumococcal vaccine coverage in adults\nPreliminary findings of the Pneumococcal pNeumonia Epidemiology\, Urine serotyping\, and Mental Outcomes (PNEUMO) US study\nBackground on invasive Hib disease and vaccination among American Indian and Alaska Native Populations\n\nThe meeting will be held on February 28\, 2024\, from 8 a.m. to 5 p.m.\, EST and February 29\, 2024\, from 8 a.m.\nto 3 p.m.\, EST (times subject to change). \nPlease visit the CDC’s Advisory Committee on Immunization Practices for the latest information. No registration is required to watch the webcasts.
URL:https://globalbiodefense.com/event/meeting-of-the-advisory-committee-on-immunization-practices-acip/
CATEGORIES:Government Hosted
LOCATION:https://video.ibm.com/channel/VWBXKBR8af4
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240411
DTEND;VALUE=DATE:20240413
DTSTAMP:20240302T211201Z
CREATED:20240302T211201Z
LAST-MODIFIED:20240302T211201Z
UID:60496-1712793600-1712966399@globalbiodefense.com
SUMMARY:NIST Rapid Microbial Testing Methods Consortium Workshop
DESCRIPTION:The NIST-led Rapid Microbial Testing Methods (RMTM) Consortium is hosting the 4th annual workshop 11-12 April 2024 to update the community on RMTM Consortium efforts and to work on Consortium deliverables. \nOver the course of two days\, independent working sessions will be hosted\, with Day 1 open to the public and Day 2 for Consortium members only. \nThis open\, virtual workshop is free of charge. All interested parties are invited to Day 1\, including advanced therapy producers\, rapid microbial testing assay/instrument developers\, and cell reference material producers. \nNew members are being accepted into the Consortium. \nPlease visit NIST’s 2024 NIST Rapid Microbial Testing Methods Consortium Workshop website for more information. \nABOUT THE RMTM \nThe NIST Rapid Microbial Testing Methods (RMTM) Consortium addresses the need for measurements and standards\, including reference materials\, to increase confidence in the use of rapid testing for microbial contaminants in regenerative medicine and advanced therapy products. \nThe safety and quality of advanced therapies\, including cell therapy\, gene therapy\, and tissue engineered products\, must be maintained prior to patient administration. The culture-based compendial methods currently used to assess product purity (specifically to ensure absence of microbial contamination) typically take weeks\, which is inadequate for patients in urgent need of life-saving therapies. These methods are also incompatible with products that have a limited shelf-life and cannot meet good manufacturing practices required in process control and release testing. Alternative rapid microbial testing methods are needed to ensure fit for purpose safety assessments for this broad class of advanced therapeutics. \nThe NIST RMTM Consortium brings together experts across the regenerative medicine field including stakeholders in industry\, academia and government to address this need.
URL:https://globalbiodefense.com/event/nist-rapid-microbial-testing-methods-consortium-workshop/
CATEGORIES:Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240603
DTEND;VALUE=DATE:20240606
DTSTAMP:20240528T155500Z
CREATED:20240528T153434Z
LAST-MODIFIED:20240528T155500Z
UID:61289-1717372800-1717631999@globalbiodefense.com
SUMMARY:Spring 2024 NSF Grants Conference
DESCRIPTION:Join the National Science Foundation (NSF) for the Spring 2024 Grants Conference from June 3 – 5\, 2024\, in Philadelphia\, PA. The event offers virtual attendance as well. \nThe NSF Grants Conference will provide up-to-date information about policies and procedures\, specific funding opportunities\, and answer attendee questions on topics including: \nResearch.gov and SciENcv Session \nNSF staff will highlight updates to NSF Research.gov. Staff from the National Institutes of Health will demonstrate SciENcv for the preparation of the biographical sketch and current and pending (other) support information. \nSciENcv is a grant application tool that helps proposers reduce administrative burden with time-saving features. This portion of the session will delve into the evolution of SciENcv\, showcase how it empowers researchers to access vital data for grant applications\, and demonstrate the enhancements added to help you generate needed forms faster than ever! \nDirectorate for Biological Sciences (BIO) \nThe mission of the Directorate for Biological Sciences (BIO) is to enable discoveries for understanding life. BIO-supported research advances the frontiers of biological knowledge\, increases our understanding of complex systems\, and provides a theoretical basis for original research in many other scientific disciplines. \nPlease visit NSF’s Grants Conference website for more information.
URL:https://globalbiodefense.com/event/spring-2024-nsf-grants-conference/
LOCATION:Philadelphia Mariott Old City\, One Dock St\, Philadelphia\, 19106\, United States
CATEGORIES:Government Hosted
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240606T130000
DTEND;TZID=America/New_York:20240606T140000
DTSTAMP:20240528T155815Z
CREATED:20240528T155815Z
LAST-MODIFIED:20240528T155815Z
UID:61299-1717678800-1717682400@globalbiodefense.com
SUMMARY:Modernized ClinicalTrials.gov Update
DESCRIPTION:ClinicalTrials.gov is the world’s largest database of privately and publicly funded clinical trials. NLM is in the final phases of a multi-year effort to modernize ClinicalTrials.gov delivering an improved user experience on an updated platform that will accommodate growth and enhance efficiency. \nDuring this webinar\, ClinicalTrials.gov staff will: \n\nShare updates on the overall modernization effort\,\nHighlight features of the modernized website\, and\nHelp users prepare for the retirement of the classic ClinicalTrials.gov.\n\nYou’ll also have an opportunity to submit questions to the speakers. \nPlease REGISTER in advance for this webinar. \nThis webinar is intended for the general public\, patients\, patient advocates\, data researchers\, data providers\, and anyone who accesses and uses the information found on ClinicalTrials.gov.
URL:https://globalbiodefense.com/event/modernized-clinicaltrials-gov-update/
CATEGORIES:Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240625T120000
DTEND;TZID=America/New_York:20240625T130000
DTSTAMP:20240624T175704Z
CREATED:20240521T200752Z
LAST-MODIFIED:20240624T175704Z
UID:61246-1719316800-1719320400@globalbiodefense.com
SUMMARY:What's in the RADx Data Hub?
DESCRIPTION:The NIH RADx Data Hub is one of the largest NIH COVID data collections available to researchers\, allowing them to explore\, access\, and analyze COVID-related data developed from over 150 studies through NIH RADx Initiative programs. \nThe NIH RADx Data Hub relaunched with an entirely new look and feel and exciting new analysis features. Join a virtual presentation on 25 June 2024 on the NIH RADx® study data collections accessible via the RADx Data Hub. \nIn this presentation\, representatives from RADx program Collection and Data Coordinating Centers ((C)DCCs) will highlight unique scientific domain areas. Presenters will discuss challenges\, illustrate their diverse study landscapes\, and overview impactful studies. RADx Data Hub Partners will then provide an overview of RADx data access requests for secondary analysis. \nPresenters and RADx Data Hub developers will be available for a live Question and Answer session\, and a recording of the event will be sent to all registrants.
URL:https://globalbiodefense.com/event/whats-in-the-radx-data-hub/
CATEGORIES:Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241114T093000
DTEND;TZID=America/New_York:20241114T170000
DTSTAMP:20241107T191142Z
CREATED:20241107T191142Z
LAST-MODIFIED:20241107T191142Z
UID:61954-1731576600-1731603600@globalbiodefense.com
SUMMARY:Integration Site Analysis During Long Term Follow-Up for Gene Therapies with Integrating Viral Vectors
DESCRIPTION:The FDA’s Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products (OTP) is hosting a virtual scientific public workshop on the clinical use of integration site analysis (ISA) during long term follow-up following administration of gene therapies with integrating viral vectors. \nIn this workshop\, FDA will convene a panel of external experts to discuss the risk of insertional mutagenesis and best practices for ISA method design\, data analysis\, and clinical interpretation. The workshop participants will include research scientists with experience in vector design and ISA\, as well as clinician-scientists with expertise in clinical interpretation of ISA data. \nFocus for this Workshop\nAs of 2024\, twelve approved and hundreds of investigational cell-based gene therapies use integrating viral vectors. While stable integration may have considerable therapeutic benefits\, integration into genomic DNA can alter host gene expression and may contribute to secondary malignancies via insertional mutagenesis. Additionally\, the choice of vector (e.g.\, lentivirus versus gammaretrovirus) and cell substrate (e.g.\, T cells versus CD34+ cells) may also contribute to this risk. \nISA is the established approach to identify vector insertion sites. However\, ISA method design and data interpretation are highly complex and product-specific. Moreover\, ISA methods may be costly and challenging to perform. There is a critical need to understand the best practices for product design and ISA method design\, execution\, and interpretation to facilitate efficient evaluation of complex gene therapy products and protect the public from potential serious adverse events. \nThis workshop will include discussions on the following topics: \n\nEffects of Cell Substrate and Vector Design on the Risk of Vector Insertion-Related Adverse Events\nISA Methodology\, Assay Design\, and Analytical Capabilities\nISA Analysis\, Quality Control\, and Data Reporting\nClinical Follow-Up for Integrating Viral Vectors\nUsing ISA to Inform Clinical Decisions\n\nFor current guidance on the role of ISA in clinical follow-up\, please refer to section V.F “Special Considerations Regarding Integrating Vectors” of the FDA Guidance for Industry “Long Term Follow-Up After Administration of Human Gene Therapy Products” dated January 2020 (https://www.fda.gov/media/113768/download). \n Registration is required.
URL:https://globalbiodefense.com/event/integration-site-analysis-during-long-term-follow-up-for-gene-therapies-with-integrating-viral-vectors/
CATEGORIES:Conference,Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250401T090000
DTEND;TZID=America/New_York:20250401T100000
DTSTAMP:20250320T183753Z
CREATED:20250320T183753Z
LAST-MODIFIED:20250320T183753Z
UID:62253-1743498000-1743501600@globalbiodefense.com
SUMMARY:USDA HPAI Poultry Innovation Grand Challenge
DESCRIPTION:U.S. Department of Agriculture Animal and Plant Health Inspection Service (APHIS) is offering a webinar on April 1\, 2025 to discuss a newly released HPAI Poultry Innovation Grand Challenge. \nThe event will assist interested applicants in learning more about the funding opportunity and how to submit a proposal. \nThe funding will support projects that will explore vaccines\, therapeutics\, research and other strategies to combat highly pathogenic avian influenza (HPAI) in poultry. \nAdvanced registration is required.
URL:https://globalbiodefense.com/event/usda-hpai-poultry-innovation-grand-challenge/
CATEGORIES:Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250930T140000
DTEND;TZID=America/New_York:20250930T170000
DTSTAMP:20250925T170137Z
CREATED:20250925T170053Z
LAST-MODIFIED:20250925T170137Z
UID:63188-1759240800-1759251600@globalbiodefense.com
SUMMARY:Strengthening and Modernizing Biosafety Oversight: Region 1 Listening Session
DESCRIPTION:On September 30\, 2025\, the National Institutes of Health (NIH)\, in collaboration with the New England Biological Safety Association\, the Northeast Biological Safety Association\, the Mid-Atlantic Biological Safety Association\, and the Chesapeake Area Biological Safety Association\, will host the first in a series of public regional listening sessions aimed at strengthening and modernizing biosafety oversight. \nThis Region 1 session will take place virtually from 2:00–5:00 PM ET and will prioritize participation from stakeholders located in Maine\, New Hampshire\, Vermont\, Massachusetts\, Connecticut\, Rhode Island\, New York\, Pennsylvania\, New Jersey\, Delaware\, West Virginia\, Maryland\, and Washington\, D.C.. \nPurpose and Objectives\nThe initiative reflects NIH’s commitment to updating its biosafety framework in light of evolving research practices and new challenges in global health security. The listening session is designed to: \n\nGather Stakeholder Input: Solicit feedback on the scope of NIH’s biosafety policy\, including whether it should continue to focus on recombinant and synthetic nucleic acids or expand to encompass wild-type biological agents\, proteins (e.g.\, toxins\, prions)\, infectious microbes\, and other hazardous biological materials.\nAssess Oversight Needs: Identify categories of research that may warrant reduced local or NIH oversight\, such as non-biomedical research under USDA or EPA purview\, FDA-regulated clinical research\, or low-risk projects involving RG1 agents or certain transgenic organisms.\nPromote Transparency and Engagement: Provide a platform for scientists\, biosafety professionals\, and other stakeholders to share their perspectives on creating a more modern\, risk-based biosafety oversight system.\n\n \nFormat and Participation\nThe session will be webcast live via NIH Videocast\, ensuring accessibility for participants across the region. Pre-registration is required\, and attendees are encouraged to indicate if they wish to provide oral comments. Requests to make comments must be submitted by September 29\, 2025. \nAll oral contributions\, as well as written feedback\, will be considered as NIH and its partners refine the direction of biosafety modernization. Importantly\, the session is free and open to the public\, reinforcing the initiative’s emphasis on inclusivity and diverse stakeholder engagement. \nWho Should Attend\nThis session is particularly relevant to: \n\nPublic health and global health security professionals\nBiosafety officers and laboratory managers\nAcademic and government researchers conducting life sciences or biomedical research\nRegulatory and compliance officials working with NIH\, USDA\, EPA\, or FDA frameworks\nEpidemiologists and infectious disease experts interested in policy intersections with research oversight\n\nLooking Ahead\nThe Region 1 event represents just the beginning of NIH’s nationwide effort. By engaging local and regional stakeholders\, NIH aims to shape a modern\, flexible biosafety oversight framework that balances scientific innovation with safety and public trust. \nFor more information\, including the draft agenda\, registration link\, and participation details\, please visit the NIH Office of Science Policy’s event webpage.
URL:https://globalbiodefense.com/event/nih-strengthening-and-modernizing-biosafety-oversight-region-1-listening-session/
CATEGORIES:Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260803
DTEND;VALUE=DATE:20260807
DTSTAMP:20260819T180141Z
CREATED:20260719T175458Z
LAST-MODIFIED:20260819T180141Z
UID:65071-1785715200-1786060799@globalbiodefense.com
SUMMARY:2026 Military Health System Research Symposium
DESCRIPTION:Advancing combat casualty care\, operational medicine\, and warfighter readiness demands a dedicated forum where the full breadth of military medical research converges — and for the Department of Defense\, that forum is the Military Health System Research Symposium. Registration for the 2026 edition opens June 29\, 2026\, at noon Eastern\, ahead of the symposium’s four-day run from August 3–6 at the Gaylord Palms Resort and Convention Center in Kissimmee\, Florida. \nThis year’s event\, themed “Harnessing the Power of Military Medical Research\,” is organized by the DoD and is expected to draw more than 3\,700 leaders\, clinicians\, scientists\, and innovators from across the military\, academia\, industry\, and international partner organizations. The theme reflects the department’s focus on accelerating research solutions that improve readiness\, performance\, survivability\, and return-to-duty outcomes for deployed service members. \nKeith Bass\, Assistant Secretary of Defense for Health Affairs and the Department of Defense’s top medical leader\, underscored the event’s significance: “MHSRS is where the military medical research community comes together to solve the hardest problems facing our deployed warfighters. The discoveries shared here directly strengthen readiness\, enhance performance\, and save lives both on and off the battlefield.” \nThe 2026 program is organized around four core research domains: warfighter medical readiness\, which addresses ensuring service members are medically prepared for deployment; expeditionary medicine\, focused on delivering advanced care in austere and contested environments; warfighter performance\, covering the optimization of physical\, cognitive\, and psychological resilience; and return to duty\, centered on accelerating recovery and reintegration following injury or illness. Presentations\, breakout sessions\, and poster sessions will span all four areas. \nMHSRS serves as the central forum for presenting research in areas including combat casualty care\, operational medicine\, infectious diseases\, rehabilitation\, and human performance. The intersection of infectious disease surveillance\, medical countermeasures\, and operational readiness makes the symposium a valuable venue for biosecurity and global health practitioners working at the civil-military interface\, or those engaged in research that supports both military and civilian health emergency preparedness. \nParticipants must register for the symposium and pay the registration fee before receiving access to room booking at the host hotel\, the Gaylord Palms Resort and Convention Center\, or the alternate partner hotel\, the Marriott Village. \nFor more information and to register\, please visit the 2026 Military Health System Research Symposium website.
URL:https://globalbiodefense.com/event/2026-military-health-system-research-symposium/
LOCATION:Gaylord Palms Resort & Convention Center\, 6000 W Osceola Pkwy\, Kissimmee\, FL\, 34746\, United States
CATEGORIES:Government Hosted
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261103
DTEND;VALUE=DATE:20261106
DTSTAMP:20260819T182005Z
CREATED:20260819T181915Z
LAST-MODIFIED:20260819T182005Z
UID:63528-1793664000-1793923199@globalbiodefense.com
SUMMARY:INTERPOL Global Biosecurity Conference 2026
DESCRIPTION:As biological threats grow more complex — spanning non-state actors\, emerging biotechnologies\, and increasingly porous borders — the need for coordinated international action across law enforcement\, public health\, and scientific communities has never been more pressing. A major international conference next autumn will bring these communities together to confront that challenge directly. \nINTERPOL’s Bioterrorism Prevention Unit will host the 2nd INTERPOL Global Biosecurity Conference from 3–5 November 2026 at INTERPOL Headquarters in Lyon\, France. The three-day conference will convene law enforcement and partner agencies\, biosecurity experts\, and academics from multiple regions and professional backgrounds to examine the current biological threat landscape and advance practical\, actionable responses. \nThe conference is designed to serve as an international forum for dialogue across sectors — including health\, customs\, civil protection\, the scientific community\, policy-makers\, and the private sector — with a shared focus on strengthening biosecurity at the global level. Specific objectives include exploring current and emerging biological threats relevant to law enforcement\, sharing good practices in prevention\, preparedness\, and incident response\, and defining concrete actions to address recommendations developed during the conference. The event builds on the inaugural Global Biosecurity Conference held in 2024. \nFor professionals working at the intersection of public health security\, biosecurity\, and global health governance\, this conference offers a rare opportunity to engage directly with law enforcement perspectives on biological threats — an increasingly critical dimension of biosecurity that extends well beyond traditional public health frameworks. Sessions will address topics ranging from early-warning systems and border biosecurity to forensic investigation of biological incidents and the dual-use risks posed by emerging technologies such as synthetic biology and AI-driven protein design. \nHighlighted sessions of interest include: \n\nGlobal biological threat landscape — Mapping the evolving landscape of non-state actors seeking to acquire\, produce\, or use biological agents and toxins as weapons\, including analysis of operational methods\, technical capabilities\, and access to open-source knowledge\nIndicators and early-warning for biological threats — Showcasing integrated intelligence frameworks combining health\, customs\, laboratory\, cyber\, and human intelligence to enhance detection\, including tools for real-time data aggregation and proactive biosecurity response\nHealth and law enforcement coordination when responding to a biological incident — Examining inter-agency decision-making\, joint command structures\, and coordination mechanisms during suspected biological incidents\, including gaps and solutions for a One Health approach\nForensic examination of bio-contaminated evidence — Outlining procedures for safe evidence preservation and presenting innovative forensic techniques for identification\, attribution\, and source tracing of biological agents or toxins used in deliberate incidents\nBiosecurity at borders — Examining integrated border control systems combining customs\, veterinary\, public health\, and law enforcement functions to detect illicit biological flows\, and discussing challenges in identifying dual-use commodities related to biological weapons\nScience\, technology\, and innovation: emerging challenges and dual-use risks to biosecurity — Identifying high-risk dual-use technologies including gene editing\, synthetic biology\, and AI-driven protein design\, and proposing proactive risk mitigation strategies and responsible innovation frameworks\nScience\, technology\, and innovation: opportunities for law enforcement — Demonstrating how technologies such as portable sequencing\, AI-powered diagnostics\, and rapid biosensors are transforming field detection and situational awareness\, with case studies of technology-enabled investigations\nMoving forward legal\, policy\, and information-sharing enablers for biosecurity — Examining legal and policy frameworks that facilitate cross-sector and international cooperation\, and identifying practical challenges and good practices in information-sharing\, evidence exchange\, and mutual assistance in the biosecurity context\n\nFor more information\, please visit INTERPOL’s Global partnerships against bioterrorism website.
URL:https://globalbiodefense.com/event/interpol-global-biosecurity-conference-2026/
LOCATION:INTERPOL Headquarters\, Lyon\, France
CATEGORIES:Government Hosted
END:VEVENT
END:VCALENDAR